A Study of LY3435151 in Participants With Solid Tumors

Last updated: August 4, 2021
Sponsor: Eli Lilly and Company
Overall Status: Terminated

Phase

1

Condition

Adenocarcinoma

Digestive System Neoplasms

Abdominal Cancer

Treatment

N/A

Clinical Study ID

NCT04099277
17364
J1Q-MC-JZIA
  • Ages > 18
  • All Genders

Study Summary

The reason for this study is to see if the study drug LY3435151 is safe in participants with advanced solid tumors.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participant must have certain types of cancer, which your study doctor will discusswith you
  • Participant must have stopped other forms of treatment for cancer, which your studydoctor will discuss with you
  • Participant must be able and willing to provide a sample of your tumor beforebeginning treatment and once while on treatment. For certain tumor types, the outcomeof the biopsy may exclude you from the study treatment (for Phase 1b)
  • Participant must agree to use birth control
  • Participant must have progressed through or are intolerant to therapies with knownclinical benefit, which your study doctor will discuss with you

Exclusion

Exclusion Criteria:

  • Participant must not have a history of tuberculosis, uncontrolled HIV or uncontrolledhepatitis B or C virus infection
  • Participant must not have an autoimmune disease, which your study doctor will discusswith you
  • Participant must not use corticosteroids, which your study doctor will discuss withyou
  • Participant must not have heart disease, Crohn's disease or brain cancer
  • Participant must not be pregnant or breastfeeding

Study Design

Total Participants: 2
Study Start date:
October 28, 2019
Estimated Completion Date:
March 05, 2020

Connect with a study center

  • Princess Margaret Cancer Centre

    Toronto, Ontario M5G 1X5
    Canada

    Site Not Available

  • National Cancer Center Hospital East

    Kashiwa, Chiba 277 8577
    Japan

    Site Not Available

  • National Cancer Center Hospital

    Chuo-Ku, Tokyo 104-0045
    Japan

    Site Not Available

  • Dana Farber Cancer Institute

    Boston, Massachusetts 02215
    United States

    Site Not Available

  • Univ of Pittsburgh Cancer Inst. (UPCI)

    Pittsburgh, Pennsylvania 15213
    United States

    Site Not Available

  • University of Texas MD Anderson Cancer Center

    Houston, Texas 77030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.